Abstract
Baseline disease-modifying therapies (DMTs) for multiple sclerosis (MS) include three different preparations of interferonbeta (IFN-β) and glatiramer acetate (GA). These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long-term safety profile for these drugs can be appraised as very good. In 2006, the therapeutic tool kit was augmented by the first monoclonal antibody, natalizumab, approved as monotherapy for treatment-refractory highly active MS. The restriction to these patient groups results from the rare, but fatal risk of JC virus-induced progressive multifocal leukoencephalopathy (PML). The first oral agent (fingolimod) was approved in 2010 for the United States and in 2011 for Europe. As a further option for therapy escalation the chemotherapeutic agent mitoxantrone is approved for non-responding relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS). The use of mitoxantrone is limited by severe cardiotoxicity and the risk of treatment related acute leukemia.
However, despite the fact that therapeutic options for MS have significantly been widened over the past decade new treatment options and more convenient modes of application are needed to enhance efficacy and improve adherence to therapy. This article will review recent developments in MS treatments focusing on oral agents (cladribine, fingolimod, BG00012, teriflunomide and laquinimod) and novel monoclonal antibodies (alemtumzumab, daclizumab, ocrelizumab, ofatumumab).
Keywords: Multiple sclerosis, cladribine, fingolimod, BG00012, laquinimod, teriflunomide, alemtuzumab, daclizumab, disease-modifying therapies (DMTs), IFN β.
Current Pharmaceutical Design
Title:Immune Therapy of Multiple Sclerosis - Future Strategies
Volume: 18 Issue: 29
Author(s): Sven G. Meuth, Kerstin Gobel and Heinz Wiendl
Affiliation:
Keywords: Multiple sclerosis, cladribine, fingolimod, BG00012, laquinimod, teriflunomide, alemtuzumab, daclizumab, disease-modifying therapies (DMTs), IFN β.
Abstract: Baseline disease-modifying therapies (DMTs) for multiple sclerosis (MS) include three different preparations of interferonbeta (IFN-β) and glatiramer acetate (GA). These substances reduce relapse rates, side-effects are tolerated by most patients and - after more than 15 years of experience - the long-term safety profile for these drugs can be appraised as very good. In 2006, the therapeutic tool kit was augmented by the first monoclonal antibody, natalizumab, approved as monotherapy for treatment-refractory highly active MS. The restriction to these patient groups results from the rare, but fatal risk of JC virus-induced progressive multifocal leukoencephalopathy (PML). The first oral agent (fingolimod) was approved in 2010 for the United States and in 2011 for Europe. As a further option for therapy escalation the chemotherapeutic agent mitoxantrone is approved for non-responding relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS). The use of mitoxantrone is limited by severe cardiotoxicity and the risk of treatment related acute leukemia.
However, despite the fact that therapeutic options for MS have significantly been widened over the past decade new treatment options and more convenient modes of application are needed to enhance efficacy and improve adherence to therapy. This article will review recent developments in MS treatments focusing on oral agents (cladribine, fingolimod, BG00012, teriflunomide and laquinimod) and novel monoclonal antibodies (alemtumzumab, daclizumab, ocrelizumab, ofatumumab).
Export Options
About this article
Cite this article as:
G. Meuth Sven, Gobel Kerstin and Wiendl Heinz, Immune Therapy of Multiple Sclerosis - Future Strategies, Current Pharmaceutical Design 2012; 18 (29) . https://dx.doi.org/10.2174/138161212802502198
DOI https://dx.doi.org/10.2174/138161212802502198 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Posterior Reversible Encephalopathy Syndrome with Atypical Presentation: A Pictorial Review on MR Imaging Features
Current Medical Imaging COMMENTARY: Transcranial Magnetic Stimulation in Multiple Sclerosis: A Method to Improve Movement
CNS & Neurological Disorders - Drug Targets Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets The Role of the Urokinase Receptor in Epilepsy, in Disorders of Language, Cognition, Communication and Behavior, and in the Central Nervous System
Current Pharmaceutical Design Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry White Matter Integrity in Subcortical Vascular Cognitive Impairment: A Multimodal Structural MRI Study
Current Alzheimer Research The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Design, Sar, and Metabolism Study of Crucifereae Family Compound (Spirobrassinin) and its Analogs for Antiangiogenic Potential Targeting Hsp90
Current Proteomics Antibody Based Therapies in Acute Leukemia
Current Drug Targets Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety HELLP Syndrome: Pathophysiology and Current Therapies
Current Pharmaceutical Biotechnology Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Current Treatment of Psoriasis with Biologics
Current Drug Discovery Technologies Acute Appendicitis as a Manifestation of the Immune Reconstitution Inflammatory Syndrome
Current HIV Research Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets